NasdaqGM - Delayed Quote USD

Tandem Diabetes Care, Inc. (TNDM)

34.97 +3.24 (+10.21%)
At close: April 23 at 4:00 PM EDT
34.97 0.00 (0.00%)
After hours: April 23 at 6:54 PM EDT
Loading Chart for TNDM
DELL
  • Previous Close 31.73
  • Open 32.55
  • Bid 34.94 x 200
  • Ask 35.02 x 400
  • Day's Range 32.51 - 35.01
  • 52 Week Range 13.82 - 40.74
  • Volume 2,348,319
  • Avg. Volume 1,737,879
  • Market Cap (intraday) 2.258B
  • Beta (5Y Monthly) 1.13
  • PE Ratio (TTM) --
  • EPS (TTM) -3.43
  • Earnings Date May 2, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 36.14

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

www.tandemdiabetes.com

2,400

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TNDM

Performance Overview: TNDM

Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TNDM
18.22%
S&P 500
6.30%

1-Year Return

TNDM
6.70%
S&P 500
22.67%

3-Year Return

TNDM
62.65%
S&P 500
22.63%

5-Year Return

TNDM
38.39%
S&P 500
74.37%

Compare To: TNDM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TNDM

Valuation Measures

Annual
As of 4/24/2024
  • Market Cap

    2.26B

  • Enterprise Value

    2.20B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.04

  • Price/Book (mrq)

    7.20

  • Enterprise Value/Revenue

    2.95

  • Enterprise Value/EBITDA

    -11.19

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -29.77%

  • Return on Assets (ttm)

    -9.63%

  • Return on Equity (ttm)

    -59.08%

  • Revenue (ttm)

    747.72M

  • Net Income Avi to Common (ttm)

    -222.61M

  • Diluted EPS (ttm)

    -3.43

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    467.91M

  • Total Debt/Equity (mrq)

    134.03%

  • Levered Free Cash Flow (ttm)

    -69.3M

Research Analysis: TNDM

Analyst Price Targets

18.00 Low
36.14 Average
34.97 Current
60.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: TNDM

Fair Value

34.97 Current
 

Dividend Score

0 Low
TNDM
Sector Avg.
100 High
 

Hiring Score

0 Low
TNDM
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
TNDM
Sector Avg.
100 High
 

Research Reports: TNDM

  • TNDM: Lowering target price to $30.00

    TANDEM DIABETES CARE INC has an Investment Rating of SELL; a target price of $30.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • TNDM: Raising target price to $31.00

    TANDEM DIABETES CARE INC has an Investment Rating of SELL; a target price of $31.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • TNDM: What does Argus have to say about TNDM?

    TANDEM DIABETES CARE INC has an Investment Rating of SELL; a target price of $30.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • TNDM: Raising target price to $30.00

    TANDEM DIABETES CARE INC has an Investment Rating of SELL; a target price of $30.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Price Target
     

People Also Watch